AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 211 min read$PTIX

ARMEN GARO H purchased $10K of PTIX

ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 16,634 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.59 on 2026-08-20.

Original reporting
SEC EDGAR · ARMEN GARO H
Published Aug 21, 2026, 12:20 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PTIX
Neutral
medium confidence
Mentioned
$PTIX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PTIXNeutralLow
01

Why it matters

The purchase modestly raises the insider's ownership but is unlikely to affect market perception significantly.

02

Market read

Routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming financing or dilution events not disclosed.

Relevance 4/10Novelty 4/10Timing: transaction dated 2026-08-20

Background

Form 4 filings disclose insider trades; this filing reports a modest purchase by the company's executive chair.

Company-level read

Ticker impact

$PTIXNeutralMedium confidence
Context

Exec chair Armen Garo H bought 16,634 shares at $0.5898 each, increasing his stake to 53,533 shares.

Expected impact

Minimal impact; price may stay flat or see slight uptick.

Evidence & confidence

Purchase amount under $10K for a micro‑cap; insider buying is positive but not material.

Market effects

Sector

None; transaction is company‑specific.

Regional

None; micro‑cap trade has no broader regional effect.

Global

None

Counterpoint

What could challenge this read

Insider purchase could be a signal of upcoming negative news, prompting caution.

Key entities

  • Company
    Protagenic Therapeutics, Inc.

    Biotech firm listed under ticker PTIX.

  • Individual
    Armen Garo H

    Executive chair and principal officer of Protagenic.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PTIX insider trading history →

Related articles

AUG 20
$PTIXMedAI 8/10

Protagenic Therapeutics, Inc.: Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder

Protagenic Therapeutics (PTIX) received FDA feedback supporting its planned Phase 1 program for PT00114, a treatment for generalized anxiety disorder. The FDA raised no objections to the program design, dose-escalation approach, or CMC and nonclinical packages. The company plans to submit the IND before the end of 2026 and target first patient dosing in the first half of 2027. PT00114 has shown promising results in preclinical and early-phase studies.

finanznachrichten.de2 min
JUL 31
$PTIXMed

Original-Research: Pentixapharm Holding AG (von NuWays AG): BUY

^ Original-Research: Pentixapharm Holding AG - from NuWays AG 31.07.2026 / 09:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.

onvista.de4 min